Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Card...

Descripción completa

Detalles Bibliográficos
Autores principales: Komajda, Michel, McMurray, John J.V., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., Jones, Nigel P., Home, Philip D.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848325/
https://www.ncbi.nlm.nih.gov/pubmed/20118174
http://dx.doi.org/10.1093/eurheartj/ehp604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848325/
https://www.ncbi.nlm.nih.gov/pubmed/20118174
http://dx.doi.org/10.1093/eurheartj/ehp604

Ejemplares similares